CoChat

STK11 /LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition

Open access
Sitthideatphaiboon, Piyada, Galan-Cobo, Ana, Negrao, Marcelo V., Qu, Xiao, Poteete, Alissa, Zhang, Fahao, Liu, Diane D., Lewis, Whitney E., Kemp, Haley N., Lewis, Jeff, Rinsurongkawong, Waree, Giri, Uma, Lee, J. Jack, Zhang, Jianjun, Roth, Jack A., Swisher, Stephen, Heymach, John V. · 2021 · Clinical Cancer Research
Cited by 111

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

Purpose: Radiotherapy with or without chemotherapy is a mainstay of treatment for locally advanced non–small cell lung cancer (NSCLC), but no predictive markers are currently available to select patients who will benefit from these therapies. In this study, we investigated the association between alterations in STK11/LKB1, the second most common tumor suppressor in NSCLC, and response to radiotherapy as well as potential therapeutic approaches to improve outcomes. Experimental Design: We conducted a retrospective analysis of 194 patients with stage I–III NSCLC, including 164 stage III patients bearing mutant or wild-type STK11/LKB1 treated with radiotherapy, and assessed locoregional recurrence (LRR), distant metastasis rates, disease-free survival (DFS), and overall survival (OS), and we investigated the causal role of LKB1 in mediating radiotherapy resistance using isogenic pairs of NSCLC cell lines with LKB1 loss or gain. Results: In stage III patients, with 4 years median follow-up, STK11/LKB1 mutations were associated with higher LRR (P = 0.0108), and shorter DFS (HR 2.530, P = 0.0029) and OS (HR 2.198, P = 0.0263). LKB1 loss promoted relative resistance to radiotherapy, which was dependent on the KEAP1/NRF2 pathway for redox homeostasis. Suppression of the KEAP1/NRF2 pathway via KEAP1 expression, or pharmacologic blockade of glutaminase (GLS) 1 sensitized LKB1-deficient tumors to radiotherapy. Conclusions: These data provide evidence that LKB1 loss is associated with LRR and poor clinical outcomes in patients with NSCLC treated with radiotherapy and that targeting the KEAP1/NRF2 pathway or GLS inhibition are potential approaches to radiosensitize LKB1-deficient tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-20-2859

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 111

Metadata

Authors
Sitthideatphaiboon, P., Galan-Cobo, A., Negrao, M. V., Qu, X., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., Rinsurongkawong, W., Giri, U., Lee, J. J., Zhang, J., Roth, J. A., Swisher, S., & Heymach, J. V.
Venue
Clinical Cancer Research
Published
2020-12-15
Volume
27
Issue
6
Pages
1720-1733
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3111311106
Cited by
111
References
18
FWCI
5.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: STK11 /LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-20-2859
The paper
Sitthideatphaiboon, P., Galan-Cobo, A., Negrao, M. V., Qu, X., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., Rinsurongkawong, W., Giri, U., Lee, J. J., Zhang, J., Roth, J. A., Swisher, S., & Heymach, J. V. (2021). STK11 /LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-20-2859

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.